secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001193125-23-103616
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio announces positive preclinical data for nsCAR platform and launches INB-330 program at AACR 2023
--------------------------------------------------------------------------------

- nsCAR platform showed ability to target cancer cells while sparing healthy tissue; ns19CAR killed 80% of leukemia cells vs 5% of healthy B cells.
- Launched INB-330 program targeting CD33 in AML; ns33CAR demonstrated anti-leukemic activity against AML, B-ALL, and CML cell lines.
- Data presented at AACR Annual Meeting 2023; management highlights potential to address previously 'undruggable' targets.
- Company seeks potential partners for further evaluation of nsCAR platform with additional targets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523103616/0001193125-23-103616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523103616/d465225d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-103616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer